Maze Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| MAZE | GPCR | KLRA | ARWR | IONS | DNLI | |
|---|---|---|---|---|---|---|
| Market cap | 1.85B | 1.45B | 1.66B | 8.71B | 6.67B | 3.35B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -10.5 | -9.6 | -3.0 | -12.4 | -35.0 | -8.9 |
| Price/book | 4.1 | 1.1 | 0.0 | 18.7 | 15.1 | 3.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +12.66% | −39.17% | −50.77% | +55.68% | −45.82% | +45.45% |
| Today | +3.50% | +0.05% | +1.75% | +3.56% | −0.67% | +7.76% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All MAZE news ›Maze Therapeutics to Participate in Upcoming Investor Conferences
The Manila Times SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney
Lisata adds biopharma finance veteran Jeffrey Farrow to board
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said it has appointed Jeffrey Farrow, a veteran biopharma finance executive, to its board of directors. Farrow fills a newly created seat, expanding the board from seven to eight members. He…
Head to Head Survey: Maze Therapeutics (NASDAQ:MAZE) and Cytokinetics (NASDAQ:CYTK)
Posted by Defense World Staff on Oct 13th, 2026 Maze Therapeutics (NASDAQ:MAZE – Get Free Report) and Cytokinetics (NASDAQ:CYTK – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two…
Analysts Are Bullish on Top Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Maze Therapeutics, Inc. (MAZE)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (VRTX) and Maze Therapeutics, Inc. (MAZE) with bullish sentiments. In a report released today, Andrew Fein from H.C.…
Maze Therapeutics initiated with a Buy at Citi
Citi initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and $50 price target The firm sees the company’s APOL1-mediated kidney di... Maze Therapeutics initiated with a Buy at Citi Citi initiated coverage of Maze Therapeutics…
Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
markets.businessinsider.com Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026 Oral presentation will highlight previously reported Phase 2 HORIZON data for MZE829 in pat
Truist sees ‘significant positive readthrough’ for Maze from Vertex data
Truist analyst Danielle Brill views Vertex’s (VRTX) positive Phase 2 topline data as a meaningful validation of APOL1 inhibition in classic APOL... Truist sees ‘significant positive readthrough’ for Maze from Vertex data Truist analyst…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com5
- defenseworld.net1
- manilatimes.net1
- proactiveinvestors.com1
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.